Invenra

Invenra company information, Employees & Contact Information

Explore related pages

Related company profiles:

Invenra offers flexible partnering options to meet diverse antibody discovery needs, from rapid, focused bispecific antibody discovery to comprehensive, collaborative development partnerships. Our new rapid bispecific discovery service, powered by the B-Body® Bispecific Platform, identifies bispecific lead panels within four months through functional screening of over 250 bispecific combinations, using mAbs derived from 90 parallel discovery screens. For those seeking a strategic, partnered approach, Invenra provides tailored support across all stages of discovery, from custom antigen design and assay development to in-depth biological analysis. This dual offering allows us to address a broad spectrum of objectives, from expedited project timelines for focused discovery services to fully integrated solutions for collaborative development partnerships.

Company Details

Employees
57
Founded
-
Address
5510 Element Way,
Phone
608-441-8319
Email
in****@****nra.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Madison, Wisconsin
Looking for a particular Invenra employee's phone or email?

Invenra Questions

News

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development - Business Wire

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development Business Wire

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board - Yahoo Finance

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board Yahoo Finance

Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform - Business Wire

Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform Business Wire

Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies - Business Wire

Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies Business Wire

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics - BioSpace

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics BioSpace

INV724 Earns FDA Orphan Drug and Rare Pediatric Drug Designations in Neuroblastoma - Targeted Oncology

INV724 Earns FDA Orphan Drug and Rare Pediatric Drug Designations in Neuroblastoma Targeted Oncology

Invenra’s bispecific antibody awarded US orphan drug designation for neuroblastoma - BioWorld MedTech

Invenra’s bispecific antibody awarded US orphan drug designation for neuroblastoma BioWorld MedTech

Invenra’s antibody gains US FDA designations for neuroblastoma treatment - Pharmaceutical Technology

Invenra’s antibody gains US FDA designations for neuroblastoma treatment Pharmaceutical Technology

Invenra, Astellas Launch Partnership Focused on Discovering Therapeutic Bispecific Antibodies - Pharmaceutical Executive

Invenra, Astellas Launch Partnership Focused on Discovering Therapeutic Bispecific Antibodies Pharmaceutical Executive

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery - The AI Journal

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery The AI Journal

Invenra, Xcellon Biologics Partner to Advance the Development of Multispecific ADCs - Contract Pharma

Invenra, Xcellon Biologics Partner to Advance the Development of Multispecific ADCs Contract Pharma

Accelerating Bispecific Antibody Discovery: From Antigens to Lead Panels in Just Four Months - Genetic Engineering and Biotechnology News

Accelerating Bispecific Antibody Discovery: From Antigens to Lead Panels in Just Four Months Genetic Engineering and Biotechnology News

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors - Stock Titan

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Stock Titan

Invenra, Astellas sign bispecific antibody discovery agreement - Pharmaceutical Business review -

Invenra, Astellas sign bispecific antibody discovery agreement Pharmaceutical Business review -

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors - BioSpace

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors BioSpace

Exelixis and Invenra partner up for oncology drug development - Pharmaceutical Technology

Exelixis and Invenra partner up for oncology drug development Pharmaceutical Technology

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs - Business Wire

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs Business Wire

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery - Business Wire

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery Business Wire

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors - Business Wire

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Business Wire

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology - Business Wire

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology Business Wire

Bispecific, Multispecific Antibodies Grapple with Cancer - Genetic Engineering and Biotechnology News

Bispecific, Multispecific Antibodies Grapple with Cancer Genetic Engineering and Biotechnology News

NimbleGen Systems, Inc. Cofounder Launches Invenra, A Competitor For Sutro Biopharma - BioSpace

NimbleGen Systems, Inc. Cofounder Launches Invenra, A Competitor For Sutro Biopharma BioSpace

Top Invenra Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant